Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its bispecific antibody drug conjugate (ADC), BL-M17D1, which is designed for the treatment of advanced solid tumors.
BL-M17D1 shares similarities with another ADC drug from Biokin, BL-B16D1, as both are developed using the company’s small molecule technology platform and incorporate a “linker+toxin” platform.- Flcube.com
